Endocrine tumors of the pancreas

Current Opinion in Oncology

Volumn 18, Issue 1, 2006, Pages 23-29

  House, Michael G ^a   Schulick, Richard D ^a,b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Islet cell tumors; MEN 1; Pancreas; Therapy

Indexed keywords

CELL PROTEIN;

ANGIOGENESIS; CANCER INVASION; CANCER SURVIVAL; CELL CYCLE; DISEASE ASSOCIATION; ENDOCRINE TUMOR; EPIGENETICS; GENE EXPRESSION; HEREDITY; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; MULTIPLE ENDOCRINE NEOPLASIA; PANCREAS ISLET CELL TUMOR; PANCREAS TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; REVIEW; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ADENOMA, ISLET CELL; BIOLOGICAL MARKERS; CARCINOMA, ISLET CELL; HUMANS; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; TRANSCRIPTIONAL ELONGATION FACTORS;

EID: 33646713167     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000198974.59239.3c     Document Type: Review

References (51)

1. Gumbs AA, Moore PS, Falconi M, et al. Review of the clinical, histological, and molecular aspects of pancreatic endocrine neoplasms. J Surg Oncol 2002; 81:45-53, discussion 54.
2. Solcia E, Kloppel G, Sobin LH, editors. Histological typing of endocrine tumours. New York NY: Springer-Verlag; 2001.
3. Wick MR, Graeme-Cook FM. Pancreatic neuroendocrine neoplasms: a current summary of diagnostic, prognostic, and differential diagnostic information. Am J Clin Pathol 2001; 115 (Suppl):S28-S45.
4. Rigaud G, Missiaglia E, Moore PS, et al. High resolution allelotype of nonfunctional pancreatic endocrine tumors: identification of two molecular subgroups with clinical implications. Cancer Res 2001; 61:285-292.
5. Esni F, Stoffers DA, Takeuchi T, Leach SD. Origin of exocrine pancreatic cells from nestin-positive precursors in developing mouse pancreas. Mech Dev 2004; 121:15-25.
6. Solcia E, Sessa F, Rindi G, et al. Classification and histogenesis of gastroenteropancreatic endocrine tumours. Eur J Clin Invest 1990; 20 (Suppl 1):S72-S81.
7. Sutliff VE, Doppman JL, Gibril F, et al. Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns. J Clin Oncol 1997; 15:2420-2431.
8. Yu F, Venzon DJ, Serrano J, et al. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol 1999; 17:615-630.
9. Maitra A, Hansel DE, Argani P, et al. Global expression analysis of well-differentiated pancreatic endocrine neoplasms using oligonucleotide microarrays. Clin Cancer Res 2003; 9:5988-5995.
10. House MG, Herman JG, Guo MZ, et al. Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. Ann Surg 2003; 238:423-431, discussion 431-432.
11. Hansel DE, Rahman A, Hermans J, et al. Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression. Mod Pathol 2003; 16:652-659.
12. Hansel DE, Wilentz RE, Yeo CJ, et al. Expression of neuropilin-1 in high-grade dysplasia, invasive cancer, and metastases of the human gastrointestinal tract. Am J Surg Pathol 2004; 28:347-356. Recent findings in the molecular pathways underlying tumorigenesis and tumor progression of the endocrine pancreas have been reported. These findings will allow the development of potential molecular markers to predict islet cell tumor behavior.
13. Nehar D, Lombard-Bohas C, Olivieri S, et al. Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf) 2004; 60:644-652. A novel serum tumor marker has been analyzed for its ability to diagnose reliably the presence of pancreatic endocrine tumors. Serum chromogranin A may serve as a reliable marker for tumor recurrence after surgical resection.
14. Marx SJ, Agarwal SK, Kester MB, et al. Multiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasias. Recent Prog Horm Res 1999; 54:397-438, discussion 438-439.
15. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997; 276:404-407.
16. Lemmens I, Van de Ven WJ, Kas K, et al. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene: the European Consortium on MEN1. Hum Mol Genet 1997; 6:1177-1183.
17. Lubensky IA, Debelenko LV, Zhuang Z, et al. Allelic deletions on chromosome 11q13 in multiple tumors from individual MEN1 patients. Cancer Res 1996; 56:5272-5278.
18. •].
19. Agarwal SK, Lee Burns A, Sukhodolets KE, et al. Molecular pathology of the MEN1 gene. Ann N Y Acad Sci 2004; 1014:189-198.
20. Guru SC, Goldsmith PK, Burns AL, et al. Menin, the product of the MEN1 gene, is a nuclear protein. Proc Natl Acad Sci USA 1998; 95:1630-1634.
21. Cupisti K, Hoppner W, Dotzenrath C, et al. Lack of MEN1 gene mutations in 27 sporadic insulinomas. Eur J Clin Invest 2000; 30:325-329.
22. Wang EH, Ebrahimi SA, Wu AY, et al. Mutation of the MENIN gene in sporadic pancreatic endocrine tumors. Cancer Res 1998; 58:4417-4420.
23. Shan L, Nakamura Y, Nakamura M, et al. Somatic mutations of multiple endocrine neoplasia type 1 gene in the sporadic endocrine tumors. Lab Invest 1998; 78:471-475.
24. Zhuang Z, Vortmeyer AO, Pack S, et al. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res 1997; 57:4682-4686.
25. Goebel SU, Heppner C, Burns AL, et al. Genotype/phenotype correlation of multiple endocrine neoplasia type 1 gene mutations in sporadic gastrinomas. J Clin Endocrinol Metab 2000; 85:116-123.
26. Moore PS, Missiaglia E, Antonello D, et al. Role of disease-causing genes in sporadic pancreatic endocrine tumors: MEN1 and VHL. Genes Chromosomes Cancer 2001; 32:177-181.
27. Stott FJ, Bates S, James MC, et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. Embo J 1998; 17:5001-5014.
28. Muscarella P, Melvin WS, Fisher WE, et al. Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/ MTS1 tumor suppressor gene inactivation. Cancer Res 1998; 58:237-240.
29. Bartsch DK, Kersting M, Wild A, et al. Low frequency of p16(INK4a) alterations in insulinomas. Digestion 2000; 62:171-177.
30. •].
31. Pavelic K, Hrascan R, Kapitanovic S, et al. Multiple genetic alterations in malignant metastatic insulinomas. J Pathol 1995; 177:395-400.
32. •].
33. Eriksson BK, Larsson EG, Skogseid BM, et al. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998; 83:2293-2301.
34. Florman S, Toure B, Kim L, et al. Liver transplantation for neuroendocrine tumors. J Gastrointest Surg 2004; 8:208-212. Surgical treatment for metastatic pancreatic endocrine neoplasms should be pursued aggressively. Liver transplantation should be considered in select patients.
35. Lang H, Oldhafer KJ, Weimann A, et al. Liver transplantation for metastatic neuroendocrine tumors. Ann Surg 1997; 225:347-354.
36. Arnold R, Simon B, Wied M. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Digestion 2000; 62 (Suppl 1):84-91.
37. Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000; 190:432-445.
38. Chen H, Hardacre JM, Uzar A, et al. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg 1998; 187:88-92.
39. Grazi GL, Cescon M, Pierangeli F, et al. Highly aggressive policy of hepatic resections for neuroendocrine liver metastases. Hepatogastroenterology 2000; 47:481-486.
40. McEntee GP, Nagorney DM, Kvols LK, et al. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 1990; 108:1091-1096.
41. Norton JA, Warren RS, Kelly MG, et al. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 2003; 134:1057-1063.
42. Que FG, Nagorney DM, Batts KP, et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995; 169:36-42.
43. Ahlman H, Wangberg B, Jansson S, et al. Interventional treatment of gastrointestinal neuroendocrine tumours. Digestion 2000; 62 (Suppl 1):59-68.
44. Anthuber M, Jauch KW, Briegel J, et al. Results of liver transplantation for gastroenteropancreatic tumor metastases. World J Surg 1996; 20:73-76.
45. Sutcliffe R, Maguire D, Ramage J, et al. Management of neuroendocrine liver metastases. Am J Surg 2004; 187:39-46.
46. Dousset B, Saint-Marc O, Pitre J, et al. Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation. World J Surg 1996; 20:908-914.
47. House MG, Cameron JL, Lillemoe KD, et al. Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer. J Gastrointest Surg (in press).
48. Karkkainen MJ, Petrova TV. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 2000; 19:5598-5605.
49. Hansel DE, House MG, Ashfaq R, et al. MAGE1 is expressed by a subset of pancreatic endocrine neoplasms and associated lymph node and liver metastases. Int J Gastrointest Cancer 2003; 33:141-147.
50. Rahman A, Maitra A, Ashfaq R, et al. Loss of p27 nuclear expression in a prognostically favorable subset of well-differentiated pancreatic endocrine neoplasms. Am J Clin Pathol 2003; 120:685-690.
51. Iino S, Abeyama K, Kawahara K, et al. The antimetastatic role of thrombomodulin expression in islet cell-derived tumors and its diagnostic value. Clin Cancer Res 2004; 10:6179-6188. Further understanding of the molecular events leading to metastatic spread of neuroendocrine tumors of the pancreas may afford novel targets for future medical therapies.